|Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD||CEO, MD & Exec. Director||579.15k||N/A||1963|
|Mr. Nigel J. Baade B.Com, Grad. Dip., CPA||CFO & Company Sec.||283.08k||N/A||N/A|
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharma Holdings Limited’s ISS governance QualityScore as of 1 July 2021 is 2. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 1; Compensation: 4.